These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

642 related items for PubMed ID: 30724387

  • 1. Long-term outcomes of patients with Crohn's disease who received infliximab or adalimumab as the first-line biologics.
    Inokuchi T, Takahashi S, Hiraoka S, Toyokawa T, Takagi S, Takemoto K, Miyaike J, Fujimoto T, Higashi R, Morito Y, Nawa T, Suzuki S, Nishimura M, Inoue M, Kato J, Okada H.
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1329-1336. PubMed ID: 30724387
    [Abstract] [Full Text] [Related]

  • 2. Comparative Effectiveness of Infliximab Versus Adalimumab in Patients with Biologic-Naïve Crohn's Disease.
    Benmassaoud A, Al-Taweel T, Sasson MS, Moza D, Strohl M, Kopylov U, Paradis-Surprenant L, Almaimani M, Bitton A, Afif W, Lakatos PL, Bessissow T.
    Dig Dis Sci; 2018 May; 63(5):1302-1310. PubMed ID: 29243105
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Does long-term efficacy differ between infliximab and adalimumab after 1 year of continuous administration?: A STROBE-compliant retrospective cohort study.
    Otake H, Matsumoto S, Mashima H.
    Medicine (Baltimore); 2017 Apr; 96(16):e6635. PubMed ID: 28422861
    [Abstract] [Full Text] [Related]

  • 6. Experience With Anti-TNF-α Biologic Agents in Succession in Patients With Crohn's Disease: A Retrospective Analysis of a Single Center.
    Ferges W, Rampertab SD, Shafqet M, Salimi Q, You G, Yousefzadeh E, Cheng JQ, Das KM.
    J Clin Gastroenterol; 2016 Apr; 50(4):326-30. PubMed ID: 25984976
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Comparative real-world outcomes between ustekinumab, infliximab, and adalimumab in bio-naïve and bio-experienced Crohn's disease patients: a retrospective multicenter study.
    Na JE, Park YE, Park J, Kim TO, Lee JH, Park SB, Kim S, Lee SB, Busan Ulsan Gyeongnam Intestinal Study Group Society (BIGS).
    BMC Gastroenterol; 2024 Sep 11; 24(1):306. PubMed ID: 39261766
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of infliximab after loss of response of/intolerance to adalimumab in pediatric Crohn's disease: A retrospective multicenter cohort study of the "GETAID pédiatrique".
    Lecoutour A, Dupont C, Caldari D, Dumant C, Vanrenterghem A, Ruiz M, Duclaux-Loras R, Berthet S, Dimitrov G, Lacroix D, Duvant P, Roman C, Wagner AC, Bourmaud A, Viala J, Ruemmele FM, Pigneur B, GETAID pédiatrique group.
    J Pediatr Gastroenterol Nutr; 2024 May 11; 78(5):1116-1125. PubMed ID: 38314896
    [Abstract] [Full Text] [Related]

  • 10. Comparison of Long-term Outcomes of Infliximab versus Adalimumab in 1,488 Biologic-Naive Korean Patients with Crohn's Disease.
    Jung YS, Han M, Park S, Cheon JH.
    Gut Liver; 2021 Jan 15; 15(1):92-99. PubMed ID: 32839359
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease.
    Cosnes J, Sokol H, Bourrier A, Nion-Larmurier I, Wisniewski A, Landman C, Marteau P, Beaugerie L, Perez K, Seksik P.
    Aliment Pharmacol Ther; 2016 Nov 15; 44(10):1102-1113. PubMed ID: 27666569
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study.
    Barberio B, Zingone F, D'Incà R, Rovigo L, Bertani L, Bodini G, Ghisa M, Gubbiotti A, Massimi D, Lorenzon G, Savarino EV.
    Clin Transl Gastroenterol; 2020 May 15; 11(5):e00177. PubMed ID: 32677808
    [Abstract] [Full Text] [Related]

  • 15. Adalimumab versus infliximab in treating post-operative recurrence of Crohn's disease: a national cohort study.
    Preda CM, Fulger LE, Negreanu L, Manuc M, Sandra I, Diculescu MM.
    Rev Esp Enferm Dig; 2016 Oct 15; 108(10):642-647. PubMed ID: 27651132
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Adalimumab vs Infliximab in Luminal Pediatric Crohn's Disease: Comparable Outcomes in a Prospective Multicenter Cohort Study.
    deBruyn JC, Huynh HQ, Griffiths AM, Jacobson K, Mack D, Deslandres C, El-Matary W, Otley AR, Church PC, Lawrence S, Wine E, Sherlock M, Critch J, Benchimol EI, Jantchou P, Rashid M, Carroll MW, Bax K, Ricciuto A, Carman N, Walters TD, Canadian Children IBD Network.
    Am J Gastroenterol; 2024 Mar 01; 119(3):565-575. PubMed ID: 37787642
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.